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ABSTRACT 
It is the third most common cancer diagnosis in both   men 
(behind prostate &lung)& women (behind breast & lung). 
Second leading cause for death after lung cancer 
Mean age at diagnosis is 5th decade 
• Sporadic colon carcinoma accounts for 70% 
• Genetic colon carcinoma accounts for    23% 
A more thorough understanding of the molecular basis for this disease, 
coupled with the development of new therapeutic approaches, has 
dramatically altered the way in which patients are managed. New 
strategies for screening and for the detection of recurrent disease have 
improved the survival of the patients. This study demonstrates the 
importance of early diagnosis and the improved prognosis and survival in 
patients with prompt surgical management. 
 
 
AIM OF THE STUDY: 
 v To analyze the clinical presentation, prognosis and outcome of 
prompt surgical management in colonic malignancies with respect 
to disease free survival rate, tumor recurrence and mortality. 
v To compare the incidence of right and left sided colonic 
malignancies and to document their clinical and pathological 
differences. 
v To elucidate the importance of CEA in determining prognosis and 
in follow-up. 
 
METHODS: 
 
This is a prospective case study of colonic malignancies with exclusion of 
genetic and familial cancers, patients with concomitant malignancies and 
severe cardiac ailments. This study was conducted with patients admitted 
to Government Royapettah hospital/Kilpauk Medical College, Chennai, 
located in the southern part of India. The study was conducted 
prospectively from the day of admission in 50 patients of colon cancers in 
various surgical units, between June 2011 and November 2013. All cases 
studied were subjected to detailed clinical examination with emphasis on 
the family history of colon cancers and duration of the presenting 
complaints and the accurate chronology of symptoms complex associated 
with each of the colonic malignancies. Colonoscopy and CT findings 
were also documented. The surgeries performed for various colon cancers 
were also recorded with postoperative complications and its influence on 
the duration of stay at hospital. A detailed workup of comparison 
between the postoperative and preoperative CEA levels was done. 
RESULT ANALYSIS AND CONCLUSION: 
 
Of the 50 cases 36 patients (72%) presented with colon cancers in their 
fifth to sixth decade of life. The colonic malignancies were found to be 
more common in males (66%) when compared to females (34%). The 
right colon cancers presented with anemia (n=26), mass abdomen (n=22) 
and loss of weight (n=28). The left colon cancers presented 
predominantly with altered bowel symptoms either constipation or loose 
stools (n=25). 70% of the cases (n=35) were right-sided tumors (located 
in caecum, ascending colon, hepatic flexure or proximal transverse colon) 
whereas the left sided tumors that of splenic flexure, descending colon 
and sigmoid colon were seen only in 30% of cases (n=15). Of the 14 
cases that showed evidence of lymph node in computerized tomography 9 
were found to be poorly differentiated adenocarcinoma, 4 were 
moderately differentiated tumors and only one was well differentiated. It 
was found that all well differentiated tumors had CEA levels ranging 
from 15 to 25ng/ml, in the range of 5 to 15ng/ml for moderately 
differentiated tumors and the poorly differentiated tumors had CEA levels 
in the range less than 5ng/ml. Of the 50 cases of carcinoma colon, 3 cases 
presented as emergencies (2 cases of obstruction and 1 was colo-vesical 
fistula). The common complications were paralytic ileus (n=20), wound 
infection (n=19), respiratory infection (n=17), sepsis (n=1) and 
anastomotic leak (n=1) in that order of frequency. Most of the cases 
(n=34) studied were of stage II disease and 10 cases were of stage III 
disease. Thus 72% of cases were of stage II and stage I. The average 
duration of postoperative stay was 11 days. However average stay in 
patients with postoperative wound infection was 15 days. The 
preoperative CEA levels were on an average above 5.5ng/ml in 
84%(n=42) of cases. However the values returned to value below the 
baseline value of 5.5ng/ml in 74%(n=37) postoperatively signifying a 
tumor free state. Of the 50 cases operated (47 elective surgeries and 3 
emergency surgeries), 3 cases of stage III/IV disease reported with 
recurrence in one year and there was 1 case of death due to septicemia in 
the case operated as an emergency. 
Based on the statistical analysis of the study it was inferred that the 
incidence of colon cancers was common in 5th to 6th decade of life and 
right colon cancers where commoner than left colon cancers. Colon 
cancers are more common in males than females. Results with respect to 
the symptom complex and duration of presenting complaints were 
confirming to the accepted knowledge about the right and left colon 
cancers. The lesions were predominantly ulcero-proliferative in right 
colon cancers but were predominantly circumferential in left colon 
cancers. It is found that there is a strong correlation between the lymph 
nodal involvement and tumor differentiation, poorly differentiated tumor 
has more propensities to cause lymph node spread early hence worse 
prognosis. The diffentiation of tumor also has inverse correlation with 
respect to CEA levels; higher the levels of CEA well differentiated will 
be the tumor grade. The common postoperative complications were 
paralytic ileus, wound infection and respiratory infection and the duration 
of postoperative stay was not related to the tumor grade or its stage but 
the presence or absence of wound infection. Postoperative CEA levels 
measured after 2 weeks is useful in assessing the surgical outcome as a 
successful surgery brings the value to baseline. Recurrent tumors had 
elevated CEA well above their immediate postoperative levels, thus 
implying the importance of postoperative follow-up of all cases operated 
for colon cancers. Lastly the mortality associated with tumor 
complicating emergency surgeries is high when compared to electively 
planned surgeries. 
Early diagnosis of colon cancers can be curative as more than 90% 
of stage I/II tumors have longer disease free survival rate than the stage 
III/IV disease. 
 
 
 
1INTRODUCTION
Colorectal lesions may be classified as either benign, potentially
malignant, or malignant based on their pathologic features. The overwhelming
majorities of colorectal tumors are of epithelial origin and arise from the
mucosal surface, where they become visible descriptively as a polyp. Benign
polyps include non-neoplastic polyps (e.g., hyperplastic, hamartomatous, or
inflammatory polyps); the potentially malignant group consists of adenomatous
polyps. Once dysplastic cells in a polyp cross the boundaries of the mucosa
(basement membrane) and start to invade the submucosa, a true cancer
(carcinoma) with the potential to metastasize is established. Tumors of
nonepithelial or mesenchymal origin are comparably rare and include, among
others, lymphoma, carcinoid and sarcoma. Significant advances have been
made in the study of colorectal cancer during last few decades. A more
thorough understanding of the molecular basis for this disease, coupled with the
development of new therapeutic approaches, has dramatically altered the way in
which patients are managed. New strategies for screening and for the detection
of recurrent disease have improved the survival of the patients. This study
demonstrates the importance of early diagnosis and the improved prognosis and
survival in patients with prompt surgical management.
2AIMS AND OBJECTIVES
? To analyze the clinical presentation, prognosis and outcome of prompt
surgical management in colonic malignancies with respect to disease free
survival rate, tumor recurrence and mortality.
? To compare the incidence of right and left sided colonic malignancies
and to document their clinical and pathological differences.
? To elucidate the importance of CEA in determining prognosis and in
follow-up.
3REVIEW OF LITERATURE
RISK FACTORS
There are various genetic and environmental risk factors associated with
the colorectal cancers event though the specific cause of the cancer in sporadic
cases is unknown. The majority of cases are however sporadic colon cancers
that typically arise within a polyp, thus nutritional and environmental factors
may play a key role in the adenoma to carcinoma progression.
Incidence of colonic malignancies is high in developed world than
developing countries and there is a sharp rise in incidence after fifth decade.
Obesity, sedentary life style, animal fat and low fiber diets are some of the risk
factors associated with the tumourigenesis. More recent prospective trials,
however, have questioned the benefit of dietary fiber supplementation in that
they were at best inconclusive and did not reduce the incidence of colorectal
cancer. Omega-3 fatty acids found in fish products have a proven beneficial
effect. It therefore could be concluded that the total amount of fats or fibers is of
lesser importance than their quality and origin. The protective effect of
vegetables and fruits may come not only from their fiber content but also from
the content of antioxidative and antiproliferative agents such as isothiocyanates
in cruciferous vegetables which may enhance the expression of carcinogen-
metabolizing enzymes and induce apoptosis in neoplastic cells.
4The mechanisms by which calcium supplements are thought to reduce
the risk of colon cancer are twofold. Calcium can bind with the bile products
and thus protecting the colonic mucosa from its irritant effects, and second, it
can interfere directly with the mucosal cells and decrease their proliferative
potential on a cellular level.
Several vitamins were found to have a cancer-protective effect. Vitamins
A, C, and E have been shown to have antioxidant activity.
Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) may
interfere with the development of colorectal neoplasms by blocking the
cyclooxygenase- dependent prostaglandin pathway. The targets are the
constitutive COX-1, as well as the cytokine-inducible COX-2, which has been
found at increased expression levels in both polyps and cancers. Several trials
therefore have studied these agents (e.g., aspirin and sulindac) for the
chemoprevention of colorectal cancer both in sporadic polyps and cancers and
in familial adenomatous polyposis (FAP).
Evidence that bile acids may act as co-carcinogens or tumor promotors
comes from both experimental and epidemiological studies. Bile acids can
induce hyperproliferation of the intestinal mucosa via a number of intracellular
mechanisms. Cholecystectomy, which alters the enterohepatic cycle of bile
acids, has been implicated in cancers of proximal colon.
5The risk of developing colon cancer is increased in smokers, alcoholics
and in those with family history of colonic malignancies. A similar, even though
proportionally lesser risk is observed for family members of individuals with
colonic adenomatous polyps.
Familial adenomatous polyposis and HNPCC have 100% and 80% risk
of developing colonic malignancies. Ulcerative colitis has 10 to 20% risk over a
period of 20 years. Surgical procedures like uretero-sigmoidostomy have
increased risk adjacent to the site of anastomosis.
PREVENTION AND SCREENING
Since symptoms are not reliable for early detection of colorectal cancer,
risk-adjusted screening programs for asymptomatic individuals are important.
Effective screening has to be based on an understanding of the adenoma-
carcinoma  sequence,  which  may  take  up  to  5  to  10  years  from  the  first
molecular  change  to  a  clinically  manifest  cancer,  and  should  reflect  an
individual's genetic and disease- or age-dependent risk for the development of
colorectal cancer. Any prevention program has to be sensitive but also practical
and cost-effective in order to achieve a broad screening of the population at risk.
The term screening is applicable only to asymptomatic people; if symptoms are
present, it is not screening but diagnostic tests that are initiated. Common tools
for screening include fecal occult blood tests, flexible sigmoidoscopies or
colonoscopies, and contrast enemas.
6PATHOGENESIS OF COLONIC CANCER
Carcinogenesis in the colon is a complex multistep process in which a
multitude of alterations have to coincide in order to transform a normal cell into
a malignant cell. Several categories of genes are involved that normally are
regulated in a sophisticated network to keep a tight balance between cell growth
and turnover, cell death, DNA replication, and mismatch repair. Disruption of
the fine balance between oncogenes, which promote cell proliferation, and
tumor suppressor genes, which inhibit excessive growth, results malignant
transformation.
COLON CANCER: A GENETIC DISEASE
  Mutations in DNA can occur either as a germ-line mutation or as a
somatic mutation. The former may be transmitted from one to the next
generation as an inherited defect. Somatic mutation occurs in a non-germ cell
confirming to the Knudson’s two hit hypothesis. Genesis of a cancer therefore
requires several independent hits to occur in one cell. One can assume that a
normal cell will be able to detect damage to its own DNA and maintain an
effective repair mechanism. However, if the cell is too severely damaged, it
might rather initiate the inherent suicide program called apoptosis. When a cell
fails to recognize or correct DNA damage and continues to replicate,
accumulation of faulty gene products within the cell eventually may lead to a
proliferative response. If that replication exceeds the growth potential of the
7neighboring normal cells, the mutation provides a growth advantage that will
increase the state of "genetic instability" and hence lead toward a malignant cell.
Despite this potential, most mutations are silent or lethal to the cell rather than
beneficial in terms of providing the cell a biologic advantage.
Two types of genetic instability may occur: at the chromosome level or
at  the  DNA  level.  A  loss  of  chromosomal  material,  i.e.,  a  chromosomal
instability (CIN), results when the chromosomes are not divided symmetrically
during mitosis such that one daughter cell receives both copies and the other
cell receives none. On an electrophoretic gel, this can be visualized as a loss of
one or more bands, which is described as loss of heterozygosity (LOH), and has
been associated with a worse prognosis of colorectal cancer. The second form
of genetic instability, at the DNA level, occurs when replication errors in
repetitive short polymorphisms lead to an additional band or bands. This
phenomenon is described as microsatellite instability (MSI), and it has been a
characteristic feature of hereditary nonpolyposis colon cancers (HNPCCs).
During the process of cell division, DNA is duplicated, with the original
DNA serving as a template for the replicated copy. DNA polymerase serves as a
"proof reader" that recognizes mismatched genes, halts the DNA synthesis,
removes the defective sequence, and then resynthesizes the DNA. Failure of the
DNA mismatch repair system predisposes to the development of mutations
within daughter cells. Consistent with the Knudson two-hit model for tumor
8suppressor genes, in all cases, inactivating mutations in both alleles are present
in the cancers that arise in affected individuals.
ADENOMA-CARCINOMA MODEL
After identifying several genetic alterations in colorectal specimens at
various stages of their neoplastic transformation and progression, Vogelstein
and colleagues in 1988 pioneered a genetic model for colorectal tumorigenesis
that since has been known as the adenoma-carcinoma sequence. This multistep
model described the carcinogenesis as an accumulation of genetic events,
uninhibited cell growth, and proliferation and clonal development. Gene
mutations and chromosomal/gene losses that were observed in sporadic colon
cancer include the APC gene (adenomatous polyposis coli), MMC gene
(mutated in colon cancer), ras, and p53. Mutations of the APC gene, which is
involved in intercellular adhesions and communications, are found in 60% of
even small adenomatous polyps, as well as in carcinomas, and therefore are
believed to occur as a very early event in carcinogenesis. Mutations of K-ras,
which under normal function plays a role in intracellular signal transduction and
stimulated cell division, occur in larger adenomas and carcinomas and are
thought to stimulate cell growth. Deletion of the tumor suppressor gene DCC
may be important in the progression from a benign polyp toward a malignant
condition. Mutations of the p53 gene, which are among the most frequent gene
mutations in human cancers, are also common in invasive colon cancers but rare
9in adenomas, suggesting that p53 mutations occur as a late event in the
development of the invasive phenotype. Thus there is a wide range of gene
mutations, inactivations, and deletions have been associated with colonic
carcinogenesis.
NONHEREDITARY COLON CANCER?
SPORADIC COLON CANCER
Sporadic colon cancer, i.e., colon cancer arising in individuals without a
family history or an inherited predisposition, accounts for approximately 60%
of all colorectal cancers and affects patients commonly above the age of 50.
FAMILIAL COLON CANCER
Familial colon cancer is the second most common and at the same time
least understood pattern of genetic colon cancer development. An association of
familial colon cancer has been found with polymorphisms, which reflect subtle
genetic changes in the form of variations in the nucleotide base sequences but
which do not affect protein structure.
HEREDITARY COLON CANCER
FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
It is an autosomal dominant condition. The offspring of affected
individuals thus have a 50% risk of inheriting FAP. However, up to 20% of
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patients with FAP are new mutations without a family history. It results because
of the truncation mutation of the APC gene in the chromosome 5q21. Variants
of the polyposis syndrome are classified as Gardener's syndrome (i.e., osteomas,
desmoid tumors, thyroid neoplasms, retinal pigment layer hypertrophy) and
Turcot's syndrome, which is associated with cerebellar medulloblastomas.
The inherited syndrome of FAP and its variants accounts for less than
1% of all colon cancers. It is characterized by greater than 100 and often several
thousand of adenomatous intestinal polyps that start to develop in the late teens
and early twenties and turn into cancer by age. An attenuated variant of the
disease is relatively rare and is characterized by a lower number and a later
onset of both the polyps and the resulting cancer. Duodenal adenomas are
common in FAP with adenocarcinoma developing in the periampullary region
in 3 to 10% of patients. The main cause of death following colectomy is due to
malignancies of duodenum and antrum. Nonadenomatous fundic polyps of
stomach usually do not have any malignant potential. Ten percent of FAP
patients develop desmoid tumors either intra-abdominally or on the abdominal
wall, extremities, and trunk. Histologically, desmoids are fibromatous lesions
consisting of large proliferation of myofibroblasts. Desmoids are lethal in 10%
and are the third most frequent cause for mortality of FAP patients, mainly
owing to the intra-abdominal variants, which cause small bowel and ureteral
obstructions.
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Nearly one third of the FAP patients have no demonstrable APC
mutation and the lesser number of polyps, late clinical presentation and
diagnosis, and decreased incidence of extra colonic manifestations as compared
with classic FAP patients. This variant of FAP is known as attenuated familial
adenomatous polyposis (AFAP).
HEREDITARY NONPOLYPOSIS COLON CANCERS (HNPCC)
Hereditary nonpolyposis colon cancer (HNPCC) is grouped as Lynch I
and II syndromes, is an inherited autosomal dominant disease that accounts for
3to 5% all colorectal cancers.
It is characterized by an early onset of colorectal cancers predominantly
but not exclusively on the right side of the colon with synchronous and
metachronous cancers. Despite its name, these cancers typically arise from
colonic polyps, but a diffuse polyposis is not present. There is 80 to 85% chance
of developing colon cancers and 40 to 50% chance of developing endometrial
cancers. Furthermore HNPCC patients are at increased risk of developing
extracolonic malignancies like tumors of ileum, gastric malignancies and that of
genito-urinary tract. The Lynch variants describe patients with predominantly
colorectal cancer at a young age (Lynch I) and those with both colorectal and
extra colonic cancers (Lynch II).
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There  is  an  established  link  between  HNPCC  and  the  DNA  MMR
system. In contrast to the gatekeeper concept applicable to the APC gene in
FAP, the mutations involve mismatch in the gene repair system thus leading to
genomic instability indirectly, thus cancer development.
In order to facilitate the clinical diagnosis off HNPCC, the Amsterdam
Criteria was first proposed in1990. The two MMR genes hMSH2 and hMLH1
were later discovered in the families coming under Amsterdam I criteria. These
genes accounted for 45 to 86% of all classic HNPCC families. There also was a
higher  risk  for hMSH2 mutation to develop extra colonic cancers like
endometrial cancer when compared with those having hMLH1 mutation.
Several other MMR genes have been identified in conjunction with HNPCC and
include hPMS1, hPMS2, and hMSH6. The ICG-HNPCC therefore revised the
criteria (Amsterdam Criteria II), which now better weigh extra colonic
manifestations (e.g., endometrial, breast, duodenum, ileum and genito-urinary
tract cancers) as part of the family history. In addition, the less restrictive
revised Bethesda Criteria were adopted to better serve patients, which carry
hMSH2 or hMLH1 gene mutations but otherwise do not fulfill the Amsterdam
Criteria. Testing for microsatellite instability (MSI) has become a valuable
diagnostic tool to identify individuals with suspected HNPCC because 85 to
90% of HNPCC tumors have MSI as opposed to only 15-20% of sporadic colon
cancers.
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AMSTERDAM CRITERIA II
?    At least three relatives with an HNPCC associated cancer (colorectal,
endometrium, small bowel, ureter, or renal pelvis). One affected relative
should be a first-degree relative of the other two.
?    At least two successive generations should be affected.
?    At least one relative should have been diagnosed before age 50 years.
?    Familial adenomatous polyposis should be excluded
BETHESDA CRITERIA (FOR IDENTIFICATION OF PATIENTS WITH
COLORECTAL TUMOR WHO SHOULD UNDERGO TESTING FOR
MSI)
? Cancer in families that meet Amsterdam criteria
? Two HNPCC-related cancers, including colorectal or extra colonic
? Colorectal cancer and a first-degree relative with colorectal cancer and/or
HNPCC-related
? Extra colonic cancer and/or colorectal adenoma: one cancer before age
45 and adenoma before age 40
? Colorectal cancer or endometrial cancer before age 45
? Right-sided colorectal cancer with an undifferentiated pattern on
histopathology before age 45
? Signet-ring cell type colorectal cancer before age 45
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Approximately 4% of colonic cancers are seen in the context of rare
syndromes. Among these are inherited hamartomatous polyposis syndromes.
Hamartomas result from a disordered differentiation during embryonic
development and are characterized morphologically by disrupted
representations of normal tissue components.
PEUTZ-JEGHERS SYNDROME
Peutz-Jeghers syndrome involves large but few colonic and small bowel
polyps that can manifest by gastrointestinal (GI) bleeding or obstruction and an
increased risk of colorectal cancer. The polyps are distinguished by a smooth
muscle band in the submucosa. Hallmark clinical features on physical
examination include freckles on the hands, around the lips, in the buccal mucosa
and periorbital regions. Associated characteristics include sinus, bronchial, and
bladder polyps, and about 5% to 10% of patients have sex cord tumors. Patients
can also develop lung and pancreatic adenocarcinomas. The gene responsible
for this syndrome is called LKB1, a serine threonine kinase. While a majority of
these patients remain relatively asymptomatic, some may present with intestinal
obstruction owing to an intussuscepted polyp and others with gastrointestinal
bleeding. Patients with Peutz-Jeghers syndrome have a moderately increased
risk in the range of 2 to 3% to develop gastrointestinal malignancies as well as
extra intestinal malignancies.
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JUVENILE POLYPOSIS SYNDROME
Juvenile polyposis has overlapping clinical manifestations with Peutz-
Jeghers, but the polyps tend to be confined to the colon, although cases of
gastric and small bowel polyps have been described and there is an increased
risk of colorectal cancer. Extra colonic manifestations are not prevalent. This is
a polygenic disease, involving germline mutations in PTEN, SMAD4, BMPR1,
or other genes yet to be identified. In infancy, patients may present as a case of
acute gastrointestinal bleeding, intussusception and malnutrition In adulthood,
patients commonly present with gastrointestinal blood loss. The polyps are
located most frequently in the recto sigmoid region.
A significant risk to develop colorectal cancers is associated with this
condition, which should not be confused with isolated juvenile polyps because
the latter have virtually no malignant potential.
COWDEN SYNDROME
Cowden's syndrome harbors hamartomatous polyps anywhere in the GI
tract, and surprisingly, there is no increased risk of colorectal cancer. However,
about 10% of patients will have thyroid tumors and nearly 50% of patients have
breast tumors. Germ line PTEN mutations have been reported.
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BANNAYAN-RILEY-RUVALCABA SYNDROME
Formerly known as its subentity, the Ruvalcaba-Myhre-Smith syndrome,
this rare autosomal dominant condition is due to the mutation of PTEN gene on
chromosome 10q23 and may be considered a variant of juvenile polyposis coli.
Hamartomatous polyps of the gastrointestinal tract with involvement of central
nervous system, thyroid and pigmentary cutaneous lesions of gentalia
characterize it. There is no proven risk of colonic malignancies or development
of extra intestinal malignancies in these patients.
CRONKITE-CANADA SYNDROME
Cronkite-Canada syndrome is characterized by diffuse polyposis and
ectodermal abnormalities such as alopecia, onychodystrophy, and skin
hyperpigmentation. The syndrome can present with diffuse polyposis of any
part of gastro intestinal tract except the esophagus. There is a certain malignant
potential associated with this condition.
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PATHOLOGY AND STAGING
HYPERPLASTIC POLYPS
Most of the colorectal polyps, particularly those of size less than 5 mm
are hyperplastic in nature and are not considered to be a precursor lesion to
cancer development. Most of the polyps were found on retrospective autopsy
analysis and they were commonly found in the recto-sigmoid region.
ADENOMATOUS POLYPS
The commonest epithelial neoplasm of colon is the adenomatous polyp,
which occurs as tubulous, tubulovillous, and villous variants. It may either be
pedunculated (with a stalk) or sessile (broad-based). By definition, the
adenomatous polyps' neoplastic nature in itself is a manifestation of colonic
dysplasia. However, different degrees of dysplasia are distinguished commonly
that parallel the likelihood of cancerous transformation. The degree of dysplasia
can be divided into three grades based on the histopathologic differentiation and
the arrangement and architecture of the epithelial cells and the acinar
complexes. Common terms for still benign polyps include low-grade dysplasia,
intermediate-grade dysplasia, and high-grade dysplasia or in situ
adenocarcinoma. The term invasive adenocarcinoma is appropriate for
neoplastic lesions that have invaded through the basal membrane and the
muscularis mucosae into the submucosa. The descriptive terms then switch to
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well differentiated (grade I), moderately differentiated (grade II), or poorly
differentiated (grade III) adenocarcinoma as additional criteria for staging.
Flat or depressed adenomas are a subtype of colonic adenomata with a
propensity for high-grade dysplasia (carcinoma in situ) in 10 to 41% of affected
patients regardless of the small size of these lesions. These lesions, which are
flat or slightly raised to less than 2 mm and commonly less than 1 cm in size,
may be overlooked easily on colonoscopy and turn into a cancer.
Chromoendoscopy techniques, have confirmed that flat adenomas represent up
to 25 to 36% of all polyps found in a random cohort. It is difficult to estimate
the likelihood that a small adenoma will progress to a larger and more
dysplastic adenoma and eventually into a cancer. A number of biologic and
molecular markers have been analyzed at predictors of a malignant potential.
Polyps may not only progress but also can regress.
Invasive carcinoma is present in 5% of all adenomas, but the incidence
correlates with the size and type of the adenoma. The Haggitt classification,
which defines four levels within the polyp, is useful in defining the degree of
invasion into a pedunculated or sessile polyp adenoma. This classification
forms the basis of the management of malignant polyps. In Haggitt levels 1, 2,
and 3, the risk of lymph node metastasis is less than 1%, whereas a level 4
invasion of the stalk behaves like a sessile lesion and carries a much higher risk
of 12 to 25% of having lymph node metastases.
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Figure 1: Showing the Appearance of Polyps
Figure 2: Showing the Colonoscopic Apprearance of a Pedunculated Polyp
When invasive cancer is found in a polyp, the management is based on
the level of invasion and the completeness of polypectomy. Based on Haggitt’s
20
observations, it has been suggested to treat pedunculated colonic cancers with
Haggitt levels 1, 2, and 3 with complete endoscopic excision or snaring,
whereas level 4 lesions should be treated as sessile T1 tumors. A sessile lesion,
which can be snared adequately in one piece and on microscopic examination
shows a clear margin of more than 2 mm, is considered adequately managed. If
a sessile lesion is removed in piecemeal technique and demonstrates
lymphovascular invasion, deep invasion into level Sm3, or has a
microscopically clear margin of less than 2 mm, the patient should undergo
colonic resection.
CARCINOMA OF THE COLON
Figure 3: Showing the Topography of Colon
Adenocarcinoma accounts for 90 to 95% of all colorectal malignancies.
Mucinous adenocarcinoma has incidence of 10% and has poor prognosis.
Signet ring cell and small cell carcinomas have less than 1% incidence and
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prognosis of very poor as almost all cases have liver and brain metastasis at the
time of presentation. Other rare types include small cell adeno-squamous,
squamous and undifferentiated medullary carcinomas.
The distribution of colorectal cancers among the various segments has
seen a continued shift toward right-sided colon cancer. Around 45 to 55% of
colon cancers are left sided whereas only 25 to 35% cancers occur on the right
side of colon. The local growth pattern for colorectal cancer involves
circumferential and transmural invasion of the tumor through the intestinal wall
into the peritoneal cavity or surrounding organ structures. Tumor dissemination
occurs primarily through access to the lymphatic vessels into the locoregional
lymph nodes or through access to the bloodstream as hematogenous metastasis
to distant organs. The most common site of blood borne spread is via the portal
venous system to the liver; other secondary locations include the lung and, less
frequently, kidneys, bone, etc. In addition, tumor dissemination can occur by
trans peritoneal seeding and result in peritoneal carcinomatosis. Following
gravity, peritoneal seeds may accumulate in the pelvic cul-de-sac or paracolic
gutters,  where they can grow to a considerable size (Blummer's shelf).  Growth
by perineural infiltration may be seen on microscopic examination and has a
negative prognostic impact. About 20% of patients have evidence of distant
metastases (stage IV disease) at the time of presentation.
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TUMOR STAGING
The TNM system classifies colorectal tumors on the basis of the
invasiveness (not size) of the primary (T stage), the number (not size or
location) of local-regional lymph nodes containing metastatic cancer (N stage),
and the presence or absence of distant metastatic disease (M stage).
T STAGE
In situ adenocarcinoma (Tis) includes cancers confined to the glandular
basement membrane or lamina propria. The terms high-grade dysplasia and
severe dysplasia are synonymous with in situ carcinoma and are also classified
as Tis. T1 tumors invade into but not through the submucosa. T2 tumors invade
into but not through the muscularis propria, and T3 tumors invade through the
muscularis propria into the subserosa or into nonperitonealized pericolic or
perirectal tissue. T4 tumors invade other named organs or structures (T4a) or
perforate the visceral peritoneum (T4b). Tumors invading other colorectal
segments by way of the serosa (i.e., carcinoma of the cecum invading the
sigmoid) are classified as T4a. A tumor that is adherent to other structures or
organs macroscopically is classified clinically as T4a; however, if the
microscopic examination of the adhesions is negative, then the pathologic
classification is pT3.
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N STAGE
Because of the prognostic significance associated with increased numbers
of lymph nodes inspected (see later discussion) the current TNM classification
scheme calls for at least 7 to 14 lymph nodes to be analyzed, and both the
number of nodes that are positive for tumor and the total number of nodes
inspected should be reported. A pN0 designation may be made even if fewer
than the recommended numbers of nodes are present; however, the prognostic
significance of this pN0 designation is weaker. N0 denotes that all nodes
examined are negative. N1 includes tumors with metastasis in one to three
regional lymph nodes (N1a:1 positive lymph node, N1b: 2-3 positive lymph
nodes, N1c:extra nodal tumor deposits). N2 indicates metastasis in four or more
regional lymph nodes (N2a: 4-6 positive nodes, N2b: >7 positive lymph nodes).
Metastatic nodules or foci found in the pericolic, perirectal, or adjacent
mesentery without evidence of residual lymph node tissue are regarded as being
equivalent to a regional node metastasis and are counted accordingly.
M STAGE
Patients are designated M0 if no evidence of distant metastases is present.
Identification of distant metastases denotes a classification of M1. Involvement
of the external iliac, common iliac, para-aortic, supraclavicular, or other
nonregional lymph nodes is classified as distant metastatic (M1) disease.
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TNM CLASSIFICATION OF COLORECTAL CANCER
STAGE T N M
0 Tis N0 M0
I T1, T2 N0 M0
IIA T3 N0 M0
IIB T4a N0 M0
IIC T4b N0 M0
IIIA
T1-T2
T1
N1/N1c
N2a
M0
M0
IIIB
T3-T4a
T2-T3
T1-T2
N1/N1c
N2a
N2b
M0
M0
M0
IIIC
T4a
T3-T4a
T4b
N2a
N2b
N1-N2
M0
M0
M0
IVA ANY T ANY N M1a
IVB ANY T ANY N M1b
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NONEPITHELIAL TUMORS OF COLON
CARCINOID OR NEUROENDOCRINE TUMORS
Carcinoid tumors may occur anywhere in the entire body. The
gastrointestinal tract is affected in 55% of cases, with the most frequent location
being the small intestine (44.7%), the rectum (19.6%), the appendix (16.7%),
and the colon (10.6%), a finding that contrasts with traditional reports that the
appendix is the most frequent site in the gastrointestinal tract. The annual
incidences for the colon and rectum were reported to be 2 and 4.2 cases per
100,000 people per year, the risk of metastasis proportional to the size of the
carcinoid. Carcinoids less than 1 cm in size are considered benign, lesions
greater  than  2  cm are  likely  malignant,  and  the  gray  zone  in  between  remains
undetermined or potentially malignant. Malignant carcinoids may spread loco-
regionally into the lymph nodes or directly to the liver. An oncologic resection
should be performed in all carcinoids larger than 2 cm, whereas the
management of tumors measuring 1 to 2 cm remains controversial.
Patients with a gastrointestinal carcinoid tumor may be either completely
asymptomatic or present with intestinal obstruction, bleeding, carcinoid
syndrome, or carcinoid heart disease (valvular right heart disease). Carcinoid
syndrome is a bad prognostic sign because it is caused metastatic lesions in the
liver that release vasoactive substances (e.g., serotonin and 5-
hydroxyindolacetic acid) directly into the systemic circulation. Diagnosis may
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be suspected clinically but is difficult to confirm histologically because the
lesions are submucosal and not commonly reached with an endoscopic biopsy.
GASTROINTESTINAL STROMAL TUMORS (GISTS)
These tumors of mesenchymal origin arise from the interstitial cells of
Cajal. Sixty  percent  of  GISTs  are  found  in  the  stomach;  29%  in  the  small
intestine; 2% in the colon, rectum, and rectovaginal septum; and 9% in the
esophagus. Symptoms are nonspecific and include pain, obstruction, bleeding,
and a mass. Distinction from other mesenchymal tumors (e.g., leiomyosarcoma)
is important from a prognostic point of view. Tumor size and light microscopic
determination of the mitotic rate. The diagnosis of GISTs is based on
morphologic features and immunohistochemical demonstration of c-Kit
(CD117) expression. This marker is seen in almost all GISTs and is regarded as
one of the key diagnostic elements but a few otherwise characteristic tumors are
found to be c-Kit-negative. Determination of CD117 expression is of practical
importance because positivity correlates with a tumor response to imatinib.
NODULAR LYMPHOID HYPERPLASIA
Numerous protruding lymphoid nodules in the mucosa of gastro
intestinal tract characterize this condition. Associated diseases are immune
deficiencies of various origins (e.g., tumors, hematoproliferative disorders,
immunoglobulin A deficiency, and HIV infection), in which case recurrent
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infections (e.g., giardiasis) appear to promote the nodular lymphoid hyperplasia.
Immunocompetent patients usually are asymptomatic. This condition is
associated with the lymphoma of small bowel.
LYMPHOMA
Primary malignant lymphoma of the colon is uncommon and accounts
for only 0.2 to 0.4% of all colonic malignancies and 10 to 15% of all primary
lymphomas the gastrointestinal tract, which themselves account for about 30%
of extra nodal lymphomas. The most frequent colonic location is the cecum
(70%), follow by the rectum and ascending colon. The gross appearance may be
a circumferential or polypoidal mass, ulceration, or a diffuse infiltration with
stricturing and bowel wall thickening. Eighty-six percent of the lesions are
solitary, but they can be multiple and diffuse in nature. The intestinal
lymphomas may be subclassified into B-cell lymphomas (85%) and T-cell
lymphomas (15%). Among these mantle cell lymphoma has worse prognosis,
whereas mucosa-associated lymphoid tissue (MALT) lymphomas have a better
prognosis. While surgical treatment may be indicated for some localized
tumors, many authors consider medical management to be the primary
treatment.
SMOOTH MUSCLE TUMORS
Smooth muscle tumors of the colon are rare and occur most commonly in
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the form of a pedunculated leiomyoma of the muscularis mucosa.
Leiomyosarcomas, which consist histologically of spindle cells that resemble
smooth muscle cells, are even less frequent but are characterized by an
extremely aggressive and rapid fatal growth pattern.
SURGICAL ANATOMY OF THE COLON
A fundamental understanding of the surgical anatomy is of utmost
importance for an adequate surgical technique that aims at the best oncologic
outcome with minimized morbidity. The large intestine starts at the ileocecal
junction and extends to the anus. It is about 5 to 6 feet long and can be divided
in  the  cecum with  the  appendix,  the  ascending colon,  the  transverse  colon,  the
descending colon, the sigmoid colon, and the rectum. Definitions of where the
sigmoid colon ends and the rectum begins have not always been uniform and
included (1) a distance of 12 to 15 cm above the anal verge, (2) the level of the
peritoneal reflection, and (3) the level of the sacral promontory. The most useful
landmark from a functional as well as surgical viewpoint is the confluence of
the teniae coli at the recto-sigmoid junction.as this important reference point
cannot be seen endoscopically, the last 12 cm above anal verge is considered
rectum. The endoscopic definition is necessary because the increasing trend
toward neoadjuvant chemo radiation for rectal but not sigmoid cancer demands
a determination whether a lesion is located in the rectum or in the sigmoid
colon.
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Figure 4: Shows the Arc of  Riolan
Figure 5: Shows the Arterial Blood supply of Colon
The arterial blood supply to the colon comes from the superior
mesenteric artery (SMA) and the inferior mesenteric artery (IMA), which
communicate in a watershed area in the splenic flexure (artery of Drummond).
The rectum has additional branches from the internal iliac vessels. With a
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significant degree of anatomic variation, the major vascular stalks to the colonic
segments consist of the ileocecal and right colic artery (last branch of the SMA),
the middle colic artery (second branch of the SMA), the left colic artery (first
branch of the IMA), and the superior hemorrhoidal artery (distal branch of the
IMA, feeding the sigmoid colon and upper rectum). The venous blood supply
peripherally follows the arterial branches but more centrally divides into the
superior mesenteric vein and the inferior mesenteric vein, which connect at
separate levels to the portal system. The lymphatic drainage starts with
lymphatic follicles in the colonic submucosa, drains through the colonic muscle
wall into the epicolic nodes, and continues to the paracolic lymph nodes that
follow the blood vessels to the bowel, along the major arteries to the principal
lymph nodes at the level the arterial runoff from the aorta. These lymph node
groups consist of the celiac, the superior mesenteric, and the inferior mesenteric
group of lymph nodes.
Figure 6: Shows the Lymphatic Drainage of Colon
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CLINICAL PRESENTATION OF COLORECTAL CANCER
SYMPTOMS
Colorectal cancer does not have any early signs. In fact, symptoms often
are absent until a tumor has grown to a significant size. Unless a patient
presents with tumor complication (e.g., bowel obstruction, bleeding,
perforation, or fistula formation), symptoms mostly are subtle or
uncharacteristic and vague. They may consist of unexplained weight loss,
anemia and weakness from chronic blood loss, flatulence, or episodes of colicky
abdominal pain. If present, these symptoms therefore always should be
suspicious for a locally relatively advanced tumor stage, which is also reflected
by the fact that 20% of colorectal cancer patients at the time of first presentation
have stage IV disease with distant metastasis. Proximal colon tumors may grow
relatively large before they interfere with the passage of the still liquid or
semisolid stool. The more distal a lesion is localized (e.g., left colon or rectum),
the more likely changes in bowel habits occur. These include bloody or mucous
discharge in or with the stool, sudden onset of constipation, alternating periods
of diarrhea and constipation, or a decreasing diameter of the stool. Pelvic or
anal pain is an ominous sign because it may occur with increasing size or
sphincter invasion of a rectal cancer. Any large bowel obstruction, bleeding per
rectum with or without peritoneal signs in an elderly should raise the index of
suspicion for a colorectal malignancy until proven otherwise.
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INVESTIGATIONS
Patients with symptoms suggestive of colorectal cancer should undergo a
series of timely investigations with three goals: (1) to assess the large bowel for
primary lesion, concomitant lesions, and a potential underlying colonic disease,
(2) to determine whether the tumor has metastasized, and (3) to assess the
patient's operability.
COLONOSCOPY
Colonoscopy clearly has evolved as the method of choice because of its
high sensitivity in detecting tumors and its ability to take biopsies. It provides
accurate information about the entire colonic mucosa (i.e., polyps, synchronous
cancer, colitis and diverticula), and it may be used to remove synchronous
neoplastic polyps. Apart from determining the circumferential and longitudinal
extent of a colonic lesion, colonoscopy addresses functional aspects such as
active bleeding or an imminent obstruction by cauterization, laser ablation, or
placement of a self-expanding wall stents.
Figure 7: Shows the Colonoscopic Appearance of Adenocarcinoma Colon
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While the overall risk of colonoscopy is very low, with a much less than
1% incidence of a bowel perforation, there are some limitations to the technique.
There is a 25% risk of smaller lesions escaping detection and an estimated 10%
incidence that the cecum may not be reached for technical reasons. In addition, the
precise position of a lesion seen on colonoscopy may not be determined
adequately because the only reliable landmarks are the dentate line and the
terminal ileum, and the length from the anal verge may vary considerably.
CONTRAST ENEMA
Radiographic contrast enemas alternatively can be used for a colonic
evaluation. They have the advantage of more accurately visualizing the anatomic
position a colonic lesion. Most commonly, a barium-air double-contrast technique
will be used; however, if there is suspicion of a colonic perforation, administration
of barium is contraindicated (risk of barium peritonitis), and instead, a water-
soluble contrast material (e.g., gastrografin) should be used. The typical aspect of
a colon cancer is a fixed filling defect with destruction of the mucosal pattern in an
annular configuration ("apple core"), as opposed to an intact mucosal pattern in a
filling defect from an extra mucosal compression or from chronic diverticulitis.
Although preoperative histologic confirmation of a colon cancer is preferable, an
unequivocal and characteristic morphology on a barium enema or endoscopy is
sufficient evidence to proceed to surgery. Contrast studies have the advantages of
a better passage through even severely obstructing lesions and that they commonly
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reach the cecum. In addition, they are superior in visualizing diverticula or a
suspected fistula between the colorectal and other pelvic organs. The major
disadvantage of contrast studies is the inability to take biopsies and to detect small
lesions.
EVALUATION OF THE LOCAL TUMOR EXTENT AND OF
METASTATIC DISSEMINATION
In contrast to rectal cancer, where endorectal ultrasound, computed
tomographic (CT) scans, and magnetic resonance imaging (MRI) are used
routinely in the preoperative work-up, a cancer of the colon does not necessarily
require further imaging studies to determine the local extent of the tumor because
in the majority of cases they do not change the local surgical approach. For a more
general preoperative evaluation of the abdomen, however, abdominal sonography,
CT scan, or MRI is indicated and equally accurate to check for the presence of
liver metastases, ascites, hydronephrosis, or gross para-aortic lymph node
involvement, a well as other concomitant diseases. CT scans are used most
commonly and have a 90% and 95% sensitivity and specificity in detecting liver
lesions greater than 1 cm. However, in some patients with liver metastasis or
undetermined liver lesions, intraoperative liver ultrasound may be an extremely
helpful tool because several studies now have shown it to be superior to
preoperative radiologic examination and intraoperative clinical assessment.
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In order to rule out extra hepatic metastases, a chest x-ray in two planes commonly
is sufficient, although the yield of this test is relatively low. A CT scan of the chest
may be necessary to substantiate a concern from conventional images. Only under
special circumstances where the presence of previously unknown tumor
manifestations (e.g., recurrence versus scar tissue, solitary versus multiple liver
metastases, and presence of extra hepatic metastases) would have an impact on the
treatment approach (e.g., operative versus non-operative) is a positron-emission
tomographic (PET) scan indicated. Routine use of PET scanning in the primary
management of colorectal cancer is not recommended.
LABORATORY AND PREOPERATIVE TESTS
Preoperative laboratory tests are aimed at providing evidence for
pathophysiologic effects of the tumor and ruling out general health problems that
could have an effect on the patients' general operability. A comprehensive work-
up includes a complete blood count, electrolytes, creatinine/blood urea nitrogen
(BUN), glucose, liver function tests (alkaline phosphatase, AST, ALT, bilirubin,
total protein, albumin), and coagulation parameters (PT, PTT, INR).
Even though tumor markers such as carcinoembryonic antigen (CEA) are
determined routinely, their role is limited because of the low sensitivity and
specificity to colonic carcinoma and because the measured value virtually never
changes the management. CEA can be elevated in proximal gastrointestinal
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cancers, benign inflammatory conditions of the bowel, lung and breast cancer, and
smoking.
“When there is return of an elevated preoperative CEA level to
normalcy indicates a complete tumor resection or when a
postoperatively elevated level may indicate residual recurrent
disease.”
Preoperative standard evaluation includes a chest x-ray in two planes for
cardiopulmonary assessment and for detection of pulmonary metastases.
Electrocardiogram (ECG) and pulmonary function tests (FVC, FEV1, and RV
diffusion capacity) are indicated in patients either older than 40 years of or with a
respective personal history. Specialized tests such as cardiac stress tests,
echocardiogram, perfusion scintigraphy, or interventional cardiologic studies
depend on the individual patient's history and risk assessment.
SURGICAL PROCEDURES
GENERAL TECHNICAL PRINCIPLES
The objective of surgery for colonic cancer is to perform a curative
resection by removing the cancerous segment of colon, the mesentery with the
primary feeding vessel and the lymphatics, and any organ with direct tumor
involvement. Since the lymphatics run with the arterial supply of the colon, the
primary artery supplying the segment of the colon to be resected is divided at its
origin. Ligation at the origin of the vessel ensures inclusion of apical nodes, which
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may convey prognostic significance for the patient. The length of bowel and
mesentery resected is dictated by tumor location and distribution of the primary
artery. Nevertheless, with radical excision of a colonic tumor, at least a 5-cm distal
and proximal clearance is required. There is no additional survival benefit with
respect to extended resections however; tumors located in "border zones" should
be resected with adjacent lymphatics to avoid possible bidirectional spread. When
synchronous cancers are present in the colon, an extended resection or even total
colectomy, with ideally only one anastomosis, should be performed. Occasionally,
two separate resections (e.g., right hemi-colectomy and low anterior resection)
with two anastomoses are preferable to preserve colon length and to avoid post
colectomy diarrhea. Cancer on the basis of an underlying pan colonic disease (e.g.,
ulcerative colitis or FAP) requires a total procto-colectomy with either an ileo-anal
pull-through procedure or an ileostomy.
Figure 8: Shows the Technique of  Right  Hemicolectomy
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Figure 9:  Shows the Technique of Right Extended Hemicolectomy
Figure 10:   Shows the Technique of Left Hemicolectomy
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Figure 11: A Right Extended Hemicolectomy Specimen
   Right hemi-colectomy is done for tumors involving caecum and ascending
colon.  Extended right hemi-colectomy is done for tumors involving hepatic
flexure and transverse colon wherein terminal ileum to splenic flexure of the colon
is resected. Extended left hemi-colectomy is done for splenic flexure growths. Left
hemi-colectomy is done for tumors of descending colon.
SPECIAL CIRCUMSTANCES IN EMERGENCY SURGERY
Tumor-related complications (e.g., bowel obstruction, perforation, or
massive bleeding) mandate emergency laparotomy, which accounts for around
20% of patients with colon cancers. Morbidity and mortality are significantly
higher than under elective conditions. The risks for wound and intra-abdominal
infections and anastomotic leakages are three to six times higher.
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TUMOR OBSTRUCTION
Sixteen percent of patients with colon cancer present with a bowel
obstruction and complain of colicky abdominal pain, abdominal distension,
vomiting, constipation, and occasionally, paradoxical diarrhea. Imaging studies
(abdominal x-ray or CT scan) characteristically demonstrate the features of a large
or small bowel obstruction depending on how proximal in the colon the
obstruction is located and whether the ileocecal valve is competent. There is risk
of caecal perforation if the diameter reaches 12 cm or more. Urgent intervention is
required in such circumstances to prevent caecal perforation. The most important
differential diagnosis is pseudo-obstruction (Ogilvie's syndrome), which is seen as
a result of various medical conditions and may mimic the features of bowel
obstruction. Every patient therefore should have a rigid proctoscopy, followed by
a water-soluble contrast enema, which should visualize only the colon up to the
site of obstruction but not beyond the stenosis because the hyperosmolar nature of
the contrast material can result in an increase in the intraluminal volume and
trigger a perforation. If the level of obstruction in the colon is proximal enough, a
resection with primary entero-colonic anastomosis, e.g., right hemi-colectomy,
extended right hemi-colectomy, or subtotal colectomy, may be carried out.
Surgeries for tumors involving left side of colon necessitates taking into
consideration certain precautions because the stool load proximal to the
obstruction is of concern for a colo-colonic anastomosis because that segment of
41
the colon could not be cleared before the operation. Synchronous lesions may
occur in up 15% of tumors presenting as obstruction, may be missed and
necessitate further intervention in the future. Obstructed left-sided tumors were
treated with a three-stage approach starting with a defunctioning loop colostomy,
followed by resection and anastomosis and last by closure of the defunctioning
stoma. The Hartmann operation is a two-stage procedure, which consists of a
recto-sigmoid resection and creation of a terminal end colostomy and rectal stump
in the first stage, followed by re-anastomosis of the colon in a second sitting.
More recently colonoscopy guided insertion of a self- expanding metallic
stents were used to relieve the acute obstruction at the tumor-bearing segment of
the colon. Successful decompression of the prestenotic colon converts the
emergency situation into an elective setting, allowing for stabilization the patient
and performance of bowel preparation. The risk of a colonic perforation during
stent placement is relatively low but acceptable because an emergency operation
would be necessary anyway if the stent could not be placed successfully. Studies
have demonstrated the safety of stent application in the cases of tumor
complicating obstruction and were found to be highly successful. A proximal
diversion may be performed with this procedure.
TUMOR-RELATED PERFORATION
Colonic perforation secondary to a tumor occurs in two different settings.
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Either a transmural tumor perforates itself, or the proximal colon becomes over
distended, particularly in the case of a competent ileocecal valve. Both conditions
may result in diffuse fecal peritonitis with significant morbidity and mortality. In
addition, the tumor perforation results in spillage of tumor cells and thus has to be
considered a stage IV tumor. Surgical management is indicated every case and
requires not only addressing the site of colonic perforation but also removing the
tumor.
MASSIVE COLONIC BLEEDING
Massive bleeding from a colonic tumor is a relatively rare complication.
Most commonly the bleeding site can be identified easily. If the patient remains
unstable and requires repeated transfusions, surgical management is indicated.
MANAGEMENT OF ADVANCED DISEASE
LOCALLY ADVANCED DISEASE
It has been estimated that approximately 15% of colonic tumors will be
adherent to adjacent organs. With locally advanced colon tumors, it is still possible
to achieve cure if resection of the involved adjacent organs is done. Unfortunately
it is difficult to distinguish between malignant adhesions from inflammatory one,
but at least 40% of these adhesions harbor malignant cells. It is therefore
imperative to perform an en-bloc resection to achieve a tumor-free margin.
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OPERABLE METASTASES
Patients with stage IV disease at the time of presentation accounts for 20
percent of all cases. Distant metastasis, particularly liver and lung are a major
cause of death in patients with colorectal carcinoma. However, patients with
asymptomatic liver metastases may have a statistically natural life expectancy of
several months up to almost 2 years without any treatment. Chemotherapy and
surgical removal of metastasis in selected patients may improve disease-free and
overall survival substantially, resulting in a cure rate of 30%. In the case of
potentially resectable metastases, resection of the colonic primary tumor therefore
should be performed with tumor-free margin status.
INOPERABLE DISSEMINATED DISEASE
In patients with unresectable metastatic disease, the surgical treatment goal
is to provide palliation and to prevent complications. In contrast to the
oncologically defined standard resections, a limited segmental wedge resection of
the colon is acceptable in this setting. Particularly tumors located in the sigmoid
colon or in the cecum and ascending colon are suitable for a laparoscopic or
laparoscopically assisted resection because these segments can be mobilized easily
a sufficient extent to ensure a safe anastomosis. If a tumor in a patient with
metastatic disease with local spread (e.g., infiltration of other organs), palliation
may be achieved by creating an internal bypass or a proximal diversion.
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COMPLICATIONS OF SURGERY
The overall perioperative mortality within 30 days of colorectal resections
is less than 2% after elective but up to 20% after emergency operations.
Complications of surgery may be of a general or surgery-specific nature and can
be classified with regard to the time of their occurrence either early (within the
first 30 days) or late (after 30 days). Intraoperative complications such as injury to
relevant anatomic structures such as ureters, spleen bowel, and duodenum are
related to the surgical technique, to blurred anatomic landmarks and layers owing
to the disease (e.g., peritonitis or massive adhesions), or to the patient's habitus
(e.g., obesity). Early surgery-specific complications include bleeding, most
frequently within the first few days of the resection, nonspecific infections, or
infections related to an anastomotic dehiscence. Other more general complications
in the early postoperative period (postoperative days 1 to 3) commonly are related
to the cardiopulmonary system and include pulmonary problems (e.g., atelectasis,
pneumonia, aspiration, and pulmonary embolism) and cardiac events (e.g.,
arrhythmia, myocardial ischemia, and dysfunction). Insufficient pain control has
been recognized as an important factor promoting these conditions because it
results in a poor respiratory effort by the patient and the inability to cough up
sputum, leading to superficial respiration and suboptimal saturation. High fever in
the 3 days therefore may be related to the development of an atelectasis rather than
to an early infection.
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Infectious complications usually occur after the third postoperative day and may
be located either intra-abdominally, in the wound, in the urinary tract, or in the
lungs. The primary work-up therefore includes bacteriologic cultures and stains,
blood and urine analysis, and a chest x-ray.
Abdominal complications consist of delayed return of upper and lower
gastrointestinal function (also referred to as postoperative ileus), fascial
dehiscence, and anastomotic breakdown. An anastomotic leak may present with
insidious symptoms such as fever, tachycardia, abdominal distension, ileus, feces
draining through a drain or the wound, or local and generalized peritonitis.
Occasionally, a leak may present with sudden deterioration, generalized
peritonitis, and septic shock as the result of a significant and rapid contamination
of the peritoneal cavity. Owing to the heterogeneous symptoms, a leak should be
suspected in any patient who is not progressing to the expected degree. Blood
parameters such as white blood cell counts and C-reactive protein may be elevated
but are nonspecific and difficult to distinguish from a normal postoperative
reaction. After an abdominal operation, normal free air should be resorbed within
7 to 10 days. The presence of substantial free sub diaphragmatic air later in the
course therefore should raise the index of suspicion for an anastomotic leak.
Imaging studies to define the presence of an anastomotic leak include a
water-soluble contrast enema to visualize extravasation of the contrast material
and/or CT scan with oral, intravenous, and possibly rectal contrast material. Apart
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from antibiotic treatment, the management of an anastomotic leak depends on its
presumed extent and the clinical presentation. A patient with generalized
peritonitis requires a re-laparotomy after appropriate resuscitation. Depending on
its location, the anastomosis either should be taken down and the ends should be
exteriorized or, in more favorable conditions, resected and a new anastomosis
performed with healthy-looking bowel ends, either with or without proximal
diversion. A local repair alone carries a high risk of failure but may succeed in
combination with drain placement and a proximal diverting ostomy. A fecal fistula
can be managed in a conservative manner if there is no evidence of generalized
peritonitis or uncontrolled sepsis. Under favorable conditions, including good
nutritional support and absence of a distal obstruction or disease of the involved
bowel segment, the fistula may close spontaneously. The surrounding skin will
need special care, and a stoma therapist will be helpful in this regard.
ADJUVANT CHEMOTHERAPY AND RADIOTHERAPY
The rationale for adjuvant chemotherapy is based on the fact that there is
still recurrence following surgical curative resections even though the incidence is
very low. 5 Fluorouracil was the first and most extensively evaluated drug for the
treatment of colorectal cancer. Studies showed only 5% improvement in survival
with adjuvant chemotherapy. However, when just those at high risk of recurrence
are treated, the improvement in survival in this group is closer to 30%. High risk
patients like those of stage III colon cancer are ideal candidates for FU/leucovorin
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based adjuvant chemotherapy for 6 months after surgery and has proven to
decrease recurrence and improve survival. The combination treatment of 5-FU/LV
for 6 months was proven to be equivalent in efficacy to 12 months. The addition of
levamisole to 5-FU/LV based regimens did not seem to add any benefit. Low-dose
LV also was demonstrated to be equally efficacious as high-dose LV when used in
combination with 5 FU.
Several new agents, e.g., irinotecan and oxaliplatin have demonstrated
significantly superior activity in combination with 5 FU/LV in the metastatic
setting. Irinotecan/5 FU/LV (FOLFIRI) and oxaliplatin/5 FU/LV (FOLFOX)
prove that the new agents in association with 5 FU/LV were superior to 5 FU/LV
alone in the treatment of stage III disease. The FOLFOX regime showed lesser
side effects though sensory neuropathy and neutropenia were commonly
associated with oxaliplatin based regimens.
Capecitabine is a oral drug that preferentially releases the active component
(5-FU) to the tumor tissue. A randomized study comparing oral capecitabine
versus intravenous 5-FU/LV concluded that capecitabine demonstrated a
statistically significantly great response rate compared with 5-FU/LV and an
equivalent time to progression and overall survival. This study demonstrated the
capecitabine is a suitable alternative to IV 5-FU and perhaps a replacement in the
future. There are currently phase II trails being conducted on
capecitabine/oxaliplatin (CAPEOX) and capecitabine/irinotecan (CAPEIRI). The
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epithelial growth factor receptor (EGFR) and vascular endothelial growth factor
(VEGF) antagonists like cetuximab and bevacizumab respectively have shown
proven benefit and can be effective as a first line drug.
Generally, radiotherapy does not play a primary role in the adjuvant treatment of
colon cancer. However, it may be considered as a loco regional field radiation in
selected locally advanced tumors.
OUTCOME AND PROGNOSIS
With the advent of better screening and diagnostic modalities there is better
outcome and survival in patients diagnosed with colorectal cancer. This may be
related to safer and more successful surgical treatment in combination with better
non-operative and adjuvant treatments. The perioperative mortality within 30 days
of elective colorectal resections is less than 2%. The 5 year survival is less than
10% for a stage 4 disease when compared to >90% for a stage 1 disease, thus
implying the significance of screening and importance of early diagnosis of
colonic malignancies.
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MATERIALS AND METHODS
This is a prospective case study of colonic malignancies with exclusion of
genetic and familial cancers, patients with concomitant malignancies and severe
cardiac ailments. This study was conducted with patients admitted to Government
Royapettah hospital/Kilpauk Medical College, Chennai, located in the southern
part of India. The study was conducted prospectively from the day of admission in
50 patients of colon cancers in various surgical units, between June 2011 and
November 2013. All cases studied were subjected to detailed clinical examination
with emphasis on the family history of colon cancers and duration of the
presenting complaints and the accurate chronology of symptoms complex
associated with each of the colonic malignancies. A thorough physical
examination was done with special emphasis on the abdomen and the relevant
clinical findings like mass, hepatomegaly, ascites, left supraclavicular
lymphadenopathy. After the clinical diagnosis of colon cancer the patients were
subjected to colonoscopy to confirm the diagnosis and the documentation of the
gross appearance of the tumor whether polypoidal, ulcerative, ulcero-proliferative
or circumferential were recorded with the location of the tumor.  Then tumor
metastatic workup is done with ultrasound and computerized tomography of
abdomen and the local nodal spread with hepatic metastasis were documented.
The histopathology reports of the colonoscopy biopsy with respect to tumor
differentiation (well differentiated, moderately differentiated or poorly
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differentiated) were recorded. In addition to the routine blood investigations, CEA
levels were recorded preoperatively. Then after the preoperative workup, the
patients were taken up for surgery based on tumor operability and the general
condition of the patient. The surgical procedures performed for various colonic
malignancies based on their location were documented. Then the postoperative
complications, which include wound infection, paralytic ileus, respiratory
infection, and anastomotic leak, were studied and the duration of stay of the
patients were also recorded. The histopathology report of the resected specimens
with respect to the tumor penetration and number of nodal spread were also
recorded and the stage of the disease was ascertained. All studied patients were
evaluated for CEA levels at their 14th postoperative day and those discharged prior
were followed up accordingly. The patients irrespective of he tumor stage were
treated with adjuvant chemotherapy with 5-FU based regimen. The discharged
patients were asked to follow up with the CEA levels every 3 months or if there is
any symptoms.
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OBSERVATION AND RESULTS
Based on data collected as per the proforma and the entries in the
Master Chart the following observations were made.
Table 1:  Age Distribution of Colon Cancers
AGE (YEARS) INCIDENCE
<30 1
31-40 8
41-50 20
51-60 16
>60 5
Bar Chart showing the Incidence of Tumors during Various Decades of Life
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Table 2: Sex Distribution of Colon Cancers
CASES MALE FEMALE
RIGHT COLON
CANCERS
24 11
LEFT COLON
CANCERS
9 6
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Table 3: Clinical Presentation of Colon Cancers
SYMPTOMS
RIGHT COLON
CANCERS
LEFT COLON
CANCERS
ANEMIA 26 3
MASS 22 2
PAIN 6 1
CONSTIPATION 5 12
LOOSE STOOLS 1 13
MALENA 11 5
BLEEDING P/R 5 9
LOSS OF WEIGHT 28 11
LOSS OF APPETITE 31 9
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Chart depicting the symptom complex of right colon cancers
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Chart depicting the symptom complex of left colon cancers
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Table 4:  Duration of Presenting Complaints
MONTHS
RIGHT COLON
CANCERS
LEFT COLON
CANCERS
1 TO 3 2 13
4 TO 6 19 2
7 TO 9 8 2
>9 4 0
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Table 5:  Tumor Appearance in Colonoscopy
CASES POLYPOIDAL ULCERATIVE
ULCERO-
PROLIFE
RATIVE
CIRCUMFE
RENTIAL
RIGHT
COLONIC
CANCERS
4 4 25 2
LEFT
COLONIC
CANCERS
0 0 6 9
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32%
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Table 6:  Shows Tumor Location and its Incidence
Chart depicting the site specific incidence of colonic malignancies
TUMOUR LOCATION INCIDENCE
CAECUM 3
ASCENDING COLON 16
HEPATIC FLEXURE 9
TRANSVERSE COLON 7
SPLENIC FLEXURE 4
DESCENDING COLON 6
SIGMOID COLON 5
59
WELL
DIFFERENTIATED
MODERATELY
DIFFERENTIATED
POORLY
DIFFERENTIATED
TUMOURS WITH NODAL
DISEASE IN CT 1 4 9
0
1
2
3
4
5
6
7
8
9
10
N
O
  O
F 
C
A
SE
S
TUMOURS WITH NODAL DISEASE
Table 7:  Shows Correlation between the Tumor Differentiation and Nodal
Disease in Computerised Tomography
TUMOUR
DIFFERENTIATION
TUMOURS WITH NODAL
DISEASE IN CT
WELL DIFFERENTIATED 1
MODERATELY
DIFFERENTIATED 4
POORLY DIFFERENTIATED 9
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Table 8:  Shows correlation between Tumor Differentiation and CEA Levels
Bar Chart Showing the CEA levels with respect to grade of tumor differentiation
TUMOUR
DIFFERENTIATION
CEA LEVELS (ng/ml)
<5 5 to 15 15 to 25 >25
WELL
DIFFERENTIATED 0 0 16 0
MODERATELY
DIFFERENTATED 0 19 0 2
POORLY
DIFFERENTATED 7 0 1 1
METASTATIC
DISEASE 0 0 1 3
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Table 9: Shows the Surgical Procedures Performed
SURGERIES PERFORMED NUMBER OF CASES
RIGHT HEMICOLECTOMY 22
RIGHT EXTENDED
HEMICOLECTOMY 13
LEFT HEMICOLECTOMY 7
LEFT EXTENDED
HEMICOLECTOMY 3
RECTOSIGMOOID RESECTION 2
HARTMANN'S PROCEDURE 2
PAUL MICKULICZ 1
Bar chart shows the number of surgical procedures performed in the cases studied
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Table 10: Shows the Number of Emergency Surgeries Performed
SURGERIES PERFORMED NUMBER OF CASES
ELECTIVE 47
EMERGENCY 3
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Table 11: Shows the Incidence of Postoperative Complications
POSTOPERATIVE
COMPLICATIONS
NUMBER OF CASES
WOUND INFECTION 19
PARALYTIC ILEUS 20
RESPIRATORY INFECTION 17
SEPSIS 1
ANASTOMOTIC
LEAK/PERITONITIS
1
Bar Diagram showing the common postoperative complications
encountered in the cases studied
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Table 12: Shows Stage Specific Incidence of Colon Cancers
TUMOUR STAGE NUMBER OF CASES
I 2
II 34
III 10
IV 4
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Table 13: Duration of Postoperative Stay
POSTOPERATIVE DURATION
OF STAY (DAYS)
NUMBER OF CASES
<10 31
10 TO 15 15
>15 4
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Table 14: Shows the Factors Affecting Postoperative Stay
CASES AND
CONSIDERATIONS
AVERAGE
POSTOPERATIVE STAY
(DAYS)
POORLY DIFFERENTIATED
TUMORS
11
STAGE III/IV DISEASE 11
POSTOPERATIVE WOUND
INFECTIONS
15
EMERGENCY SURGERIES 19
Bar Chart shows various factors affecting the duration of postoperative stay
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Table 15: Shows Preoperative CEA Levels
CEA LEVELS
(ng/ml)
PRE-OPERATIVE
CASES
POST-OPERATIVE
CASES
<2.5 3 9
2.5 TO 5.5 5 28
5.5 to 7.5 13 11
>7.5 29 0
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Table 16: Shows Stage Specific Recurrence in Advanced Tumors
TUMOR STAGE RECURRENCE
STAGE I 0
STAGE II 0
STAGE III 2
STAGE IV 1
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Table 17: Shows Comparison of CEA Levels in Recurrent Cases
PREOPERATIVE POSTOPERATIVE
3RD
MONTH
6TH
MONTH
CASE
1 2.7 2.5 6.7 18.8
CASE
2 2.8 2.6 8.6 24.8
CASE
3 26.3 4.8 9.7 20.6
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Table 18: Shows the Incidence of Recurrence and Mortality
DISEASE FREE SURVIVAL RECURRENCE MORTALITY
46 3 1
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DISCUSSION
After analyzing the statistical data of the study, we could arrive at the
following valuable inferences with respect to the colonic malignancies in our
hospital setup.
AGE DISTRIBUTION
Majority of the cases happened to fall in the 5th and 6th decade group. Of the
50 cases 36 patients (72%) presented with colon cancers in their fifth to sixth
decade of life, this is in conformity to the global incidence of tumor in this age
group.
SEX DISTRIBUTION
The incidence of right colonic malignancies (70%) was more than that of
the left colonic malignancies (30%) in both sexes. The colonic malignancies were
found to be more common in males (66%) when compared to females (34%).
PRESENTING COMPLAINTS
The right colon cancers presented with anemia (n=26), mass abdomen
(n=22) and loss of weight (n=28). The left colon cancers presented predominantly
with altered bowel symptoms either constipation or loose stools (n=25).
DURATION OF PRESENTING COMPLAINTS
It is a known fact that the presentation of the right colonic malignancies is
delayed when compared to left colonic tumors due to the gross pathology of the
tumor being predominantly ulcero-proliferative on the right side whereas it is
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predominantly circumferential in the left side, also being compounded by the stool
consistency. My study revealed that the average duration of complaints for the
right colonic malignancies is 5 months whereas it is 2 months for left colonic
malignancies.
COLONOSCOPIC APPEARANCE OF TUMOR AND LOCATION
The right colon tumors were predominantly ulcero-proliferative whereas
the left colon tumors mostly presented as a circumferential growth, thus explaining
the longer duration of symptomatology as evidenced above. 70% of the cases
(n=35) were right-sided tumors (located in caecum, ascending colon, hepatic
flexure or proximal transverse colon) whereas the left sided tumors that of splenic
flexure, descending colon and sigmoid colon were seen only in 30% of cases
(n=15).
TUMOR DIFFERENTIATION AND LYMPHNODE STATUS
Of the 14 cases that showed evidence of lymph node in computerized
tomography 9 were found to be poorly differentiated adenocarcinoma, 4 were
moderately differentiated tumors and only one was well differentiated. Thus
implying the important association of lymph node spread with respect to tumor
differentiation, poorer the tumor differentiation more is the chance of lymphatic
spread and hence worse prognosis.
CORRELATION BETWEEN CEA AND TUMOR DIFFERENTIATION
All cases had were evaluated for CEA (carcino-embryonic antigen)
preoperatively and compared with diffentiation of tumor following the
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histopathological report of colonoscopic biopsy. It was found that all well
differentiated tumors had CEA levels ranging from 15 to 25ng/ml, in the range of
5 to 15ng/ml for moderately differentiated tumors and the poorly differentiated
tumors had CEA levels in the range less than 5ng/ml. Thus we infer that the CEA
levels are inversely related to the differentiation of the tumor. One other important
finding is that all the tumors with liver secondaries had high levels of CEA
(>25ng/ml).
SURGERIES PERFORMED
The incidence of right colon cancers being more, the surgical procedures
like right hemi-colectomy and exented right hemi-colectomy were predominantly
done when compared to left hemi-colectomy, left extended hemi-colectomy or
recto-sigmoid resection.
Of the 50 cases of carcinoma colon, 3 cases presented as emergencies (2
cases of obstruction and 1 was colo-vesical fistula). Incidentally all cases that
presented with obstruction were sigmoid colonic malignancies. Hartmann’s
procedure was done for cases of obstruction and modified supralevator pelvic
exenteration with end colostomy was done for colo-vesical fistula.
POSTOPERATIVE COMPLICATIONS
The common complications were paralytic ileus (n=20), wound infection
(n=19), respiratory infection (n=17), sepsis (n=1) and anastomotic leak (n=1) in
that order of frequency. Although respiratory and wound infections have other
variables (comorbid illness like diabetes, cancer cachexia, postoperative wound
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management) to be factored in, around 40% of patients with wound infection had
longer postoperative stay.
TUMOR STAGE
After the pathologic analysis of the resected specimen accurate details with
respect to depth of tumor spread and the node positivity, stage of the disease was
ascertained. Most of the cases (n=34) studied were of stage II disease and 10 cases
were of stage III disease. Thus 72% of cases were of stage II and stage I.
DURATION OF POSTOPERATIVE STAY
The average duration of postoperative stay was 11 days. However average
stay in patients with postoperative wound infection was 15 days. Both the tumor
stage and differentiation had no bearing on the duration of postoperative stay.
PREOPERATIVE VS POSTOPERATIVE CEA LEVELS
The CEA levels were measured on the 14th postoperative day and compared
with the preoperative levels. The preoperative CEA levels were on an average
above 5.5ng/ml in 84%(n=42) of cases. However the values returned to value
below the baseline value of 5.5ng/ml in 74%(n=37) postoperatively signifying a
tumor free state. This fall in CEA levels postoperatively is an important predictor
of the surgical outcome.
RECURRENCE AND MORTALITY
Of the 50 cases operated (47 elective surgeries and 3 emergency surgeries),
3 cases of stage III/IV disease reported with recurrence in one year and there was
1 case of death due to septicemia in the case operated as an emergency. The CEA
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levels in the recurrent cases were found elevated during follow-up. Thus it could
be inferred that the mortality rate following a tumor complicating emergency
surgery is high (30%) when compared to elective surgeries. Also the elevation of
CEA in tumor recurrence signifies the importance of regular follow up of all cases
postoperatively with serial monitoring of CEA levels (once in every 3 months for
one year followed by every 6 months).
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CONCLUSION
Based on the statistical analysis of the study it was inferred that the
incidence of colon cancers was common in 5th to 6th decade of life and right colon
cancers where commoner than left colon cancers. Colon cancers are more common
in males than females. Results with respect to the symptom complex and duration
of presenting complaints were confirming to the accepted knowledge about the
right and left colon cancers. The lesions were predominantly ulcero-proliferative
in right colon cancers but were predominantly circumferential in left colon
cancers. It is found that there is a strong correlation between the lymph nodal
involvement and tumor differentiation, poorly differentiated tumor has more
propensity to cause lymph node spread early hence worse prognosis. The
diffentiation of tumor also has inverse correlation with respect to CEA levels;
higher the levels of CEA well differentiated will be the tumor grade. The common
postoperative complications were paralytic ileus, wound infection and respiratory
infection and the duration of postoperative stay was not related to the tumor grade
or its stage but the presence or absence of wound infection. Postoperative CEA
levels measured after 2 weeks is useful in assessing the surgical outcome as a
successful surgery brings the value to baseline. Recurrent tumors had elevated
CEA well above their immediate postoperative levels, thus implying the
importance of postoperative follow-up of all cases operated for colon cancers.
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Lastly the mortality associated with tumor complicating emergency surgeries is
high when compared to electively planned surgeries.
Early diagnosis of colon cancers can be curative as more than 90% of stage I/II
tumors have longer disease free survival rate than the stage III/IV disease.
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PROFORMA
NAME: AGE: SEX:
ADDRESS: UNIT:
I.P NO:
OCCUPATION:
D.O.A:                           D.O.S D.O.D:
PRESENTING COMPLAINTS:
DURATION OF COMPLAINTS:
PAST HISTORY:
PERSONAL HISTORY:
PHYSICAL EXAMINATION:
Consciousness
Orientation
Hydration status:
Anemia:
Jaundice:
Vitals:
CVS:
RS:
Abdomen:
CNS:
P/R
External genitalia:
INVESTIGATIONS:
Colonoscopy
Computerized tomography
Blood parameters:
Renal function test
Serum electrolytes
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Complete haemogram
Liver function tests
CEA levels
Stool for occult blood
X RAY chest
OPERATIVE PROCEDURE:
TUMOR STAGE:
POST OPERATIVE PERIOD:
Fever
Wound infection
Wound dehiscence
Respiratory tract infection
Paralytic ileus
Sepsis
Anastomotic leakage/peritonitis
DURATION OF STAY IN HOSPITAL:
POSTOPERATIVE CEA (POD 14)
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ABBREVIATIONS
M - MALE
F - FEMALE
A - ANEMIA
M - MASS
P - PAIN
D - DURATION OF PRESENTING COMPLAINTS
IN MONTHS
P - POLYPOIDAL
C - CIRCUMFERNTIAL
U - ULCERATIVE
N - NO
R - RECURRENCE
D - DEATH
LS - LOOSE STOOLS
UP - ULCERO PROLIFERATIVE
AC - ASCENDING COLON
HF - HEPATIC FLEXURE
TC - TRANSVERSE COLON
SF - SPLENIC FLEXURE
DC - DESCENDING COLON
SC - SIGMOID COLON
LN - LYMPH NODE
WD - WELL DIFFERENTIATED
MD - MODERATELY DIFFERENTIATED
PD - POORLY DIFFERENTIATED
RH - RIGHT HEMICOLECTOMY
LH - LEFT HEMICOLECTOMY
LR - LIVER RESECTION
PI - PARALYTIC ILEUS
WI - WOUND INFECTIO
RI - RESPIRATORY INFECTION
MLN - MALENA
BPR - BLEEDING PER RECTUM
LOW - LOSS OF WEIGHT
LOA - LOSS OF APPETITE
REH - RIGHT EXTENDED HEMICOLECTOMY
LEH - LEFT EXTENDED HEMICOLECTOMY
RSR - RECTOSIGMOID RESECTION
POC - POST OPERATIVE COMPLICATIONS
CVF - COLOVESICAL FISTULA
CONST - CONSTIPATION
METS - METASTASIS TO LIVER
OBST - OBSTRUCTION
PODD - POST OPERATIVE DAY OF DISCHARGE.
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MASTER CHART
NO NAME AGE SEX IP NO COMPLAINTS D TYPE/SITE
LN/M
ETS GRADE
EMER
GENC
Y
SURGERY TUMORSTAGE POC
POD
D
CEA (ng/ml) R/
DPre Post 3m 6m
1
JEYAVEL 60 M 101990 A, LOW/LOA 4 UP/HF NIL MD N REH II NIL 9 5.6 2.1 2.0 2.3 N
2 MOTHILAKSHMI 49 F 119517
A, M, P,
LOW/LOA 6 UP/AC NIL WD N RH II NIL 9 16.5 2.3 2.5 2.4 N
3 RAJESH 28 M 21395 MLN, BPR, P,LOW/LOA 3 UP/TC LN+ PD N RH III PI, WI 15 2.4 2.0 2.2 2.1 N
4 GOVINDARAJ 48 M 111399
A, M, CONST,
LOW/LOA 8 UP/TC NL MD N REH II NIL 9 7.5 4.2 3.1 2.2 N
5 RAVISHANKAR 47 M 112143
A, BPR, CONST,
LS 2 C/DC
LN+/
M+ MD N LH&LR IV
PI, WI,
RI 14 31.3 5.6 4.7 4.1 N
6
ANTONY
PRAKAS
H
44 M 109328 A, BPR, CONST,LS, LOW/LOA 5 C/SC NIL WD N RSR II WI 11 16.5 4.6 3.5 2.8 N
7 RAVI 51 M 107559 A, M, MLN,LOW 12 UP/AC NIL MD N RH II NIL 9 8.5 4.8 4.4 3.2 N
8 SASIKUMAR 38 M 103891 A, LOW/LOA 3 UP/AC
LN+/
M+ PD N RH&LR IV PI, RI 13 22.3 2.1 2.2 2.0 N
9 JAYAPANDIAN 64 M 102779
A, M,
LOW/LOA 6 UP/HF NIL MD N REH II NIL 9 8.6 5.8 3.8 1.9 N
10 KANAGAVALLI 46 F 996917 M, P, LOW/LOA 8 UP/AC NIL WD N RH II PI 9 18.9 5.6 4.6 2.7 N
11
VAITHIY
ALINGA
M
40 M 996213 MLN, LS,LOW/LOA 5 UP/SF NIL MD N LEH II RI, WI 18 9.6 6.8 4.3 3.1 N
12 SAYEDABBAS 64 M 994163 A, P, LOW/LOA 12 UP/HF LN+ PD N REH III PI 9 2.4 2.2 2.1 1.8 N
13 JAMAL 40 M 989468 M, LOA/LOW 9 U/CAECUM NIL WD N RH II RI 9 16.6 4.2 3.5 2.7 N
14 VELU 60 M 989250 A, CONST, BPR,LOW/LOA 4 UP/TC NIL MD N REH II WI, PI 12 7.2 5.5 4.0 2.6 N
15 VISALAKSHI 64 F 995366
A, M, MLN,
LOA 6 U/AC NIL WD N RH II RI 9 19.3 4.8 3.5 2.6 N
16 BABU 50 M 981524 A, M, P,LOW/LOA 4 UP/AC NIL MD N RH II PI 9 7.2 4.8 3.2 2.1 N
17 KARUNAKARAN 59 M 983432
M, CONST,
LOW/LOA 5 UP/AC LN+ PD N RH III WI, RI 15 2.7 2.5 6.7 18.8 R
18 BABU 56 M 986415 M, LOW/LOA 4 P/HF NIL MD N REH I PI 9 6.2 2.8 2.5 1.8 N
19 KRISHNAN 70 M 977546 M, MLN, LOA 6 UP/HF NIL WD N RH II WI, RI 14 17.7 5.3 4.1 3.6 N
20 SRINIVASAN 42 M 972841 A, M, LOA 5 UP/AC NIL MD N RH II PI 9 6.3 4.7 3.2 2.5 N
21 RAJA 53 M 113267 M, P, MLN,LOA 6 P/AC NIL MD N RH II WI, RI 12 7.8 3.5 2.7 2.1 N
22 MUNUSAMY 48 M 11495
P, BPR, LS,
LOW/LOA 2 UP/SC NIL MD CVF HP II WI, P 26 8.9 4.4 3.5 2.5 N
23 KALAISELVI 58 F 12610
A, M, CONST,
BPR, LOW/LOA 3 UP/SF LN+ PD N LEH III PI 9 2.8 2.6 8.6 24.8 R
24 SHANTHI 50 F 15058 CONST, LS,LOW/LOA 1 C/DC
LN+/
M+ MD N LH&LR IV WI 16 26.3 4.8 9.7 20.6 R
25 ALLIMUTHU 50 M 17179
A, M,
LOW/LOA 6 UP/HF NIL MD N REH II PI, RI 9 5.9 4.3 3.5 1.8 N
26 CHANDRA 43 F 17327
CONST, LS,
BPR, LOA 2 C/SC
LN+/
M+ PD OBST HP IV
WI,RI,
SEPSIS 10 32.8 D
27 SAKUNTALA 55 F 17620 A, LOW/LOA 8 UP/AC NIL MD N RH II PI 9 6.5 4.9 3.5 2.1 N
28 GOVINDASAMY 65 M 21748
MLN, CONST,
LS, LOW/LOA 2 C/SC LN+ PD N RSR III NIL 9 2.8 2.1 2.2 1.8 N
29 MARIMUTHU 55 M 110163
A, MLN,
LOW/LOA 4 UP/HF NIL MD N REH II WI 12 7.2 4.7 4.1 2.6 N
30 RAJA 53 M 113267 A, LOW 8 P/AC NIL MD N RH II NIL 9 8.6 5.1 3.5 2.2 N
31 DURAIRAJ 40 M 105746
A, M, MLN,
LOW/LOA 7 UP/AC NIL WD N RH II PI, RI 9 16.2 4.8 3.1 1.8 N
32 RAJESHWARI 35 F 109662
A, M,
LOW/LOA 9 UP/HF LN+ MD N REH III WI 12 8.8 4.7 2.7 1.7 N
33 SHANTHI 45 F 111381 M, LS, CONST,BPR, LOW 3 UP/SF NIL WD N LEH II PI 9 16.8 5.2 3.6 2.1 N
34 VENKAT 44 M 114742 LS, BPR,CONST 2 C/SC NIL WD OBST PMP II
PI, WI,
RI 20 19.8 5.8 3.7 2.5 N
35 DEVI 35 F 113915 A, MLN, BPR,LOW/LOA 5 UP/TC NIL MD N REH II NIL 9 6.2 4.3 2.8 2.1 N
36 RAGHINI 51 F 991978 A, M,LOW/LOA 9
UP/CAE
CUM NIL WD N RH II PI 9 15.5 5.0 3.2 1.7 N
37 THIMMARAYAN 52 M 12609
CONST, LS,
BPR, LOW/LOA 2 C/DC LN+ MD N LH III WI, RI 14 8.2 5.2 3.8 2.2 N
38 SHANKAR 38 M 114078
A, M, CONST,
BPR, MLN 4 C/TC LN+ WD N REH III NIL 9 18.3 4.8 4.4 2.8 N
39 MANI 48 M 113875 A, LOW/LOA 6 UP/HF NIL MD N REH II WI 12 6.3 4.2 4.1 2.7 N
40 FATHIMA 40 F 112140 A, CONST,LOW/LOA 3 C/DC LN+ PD N LH III NIL 9 2.2 2.0 2.1 1.8 N
41 SUGUNA 58 F 112876 LS, MLN, LOW 3 UP/SF NIL MD N LEH II PI, RI 9 8.3 4.7 3.5 2.8 N
42 SUMATHI 50 F 168738 A, M, LOA 6 UP/AC NIL WD N RH II NIL 9 16.5 4.8 4.1 3.2 N
43 VASANTH 47 M 106376
A, M, CONST,
LOW/LOA 4 C/TC NIL WD N REH II WI, RI 14 18.8 5.2 4.5 2.8 N
44 ELUMALAI 43 M 105783
LS, CONST,
BPR, MLN,
LOW
2 UP/DC NIL MD N LH II PI 9 5.8 4.2 3.6 1.7 N
45 MEGHALA 60 F 104378
A, MLN,
LOW/LOA 8 U/AC NIL PD N RH II NIL 9 2.8 2.2 2.3 1.8 N
46 LALITHA 46 F 103876
M, CONST,
MLN,
LOW/LOA
7 UP/TC NIL WD N RH II PI 9 21.1 4.9 3.1 2.9 N
47 MOHAN 59 M 137865 A, M,LOW/LOA 11
U/CAEC
UM NIL WD N RH II NIL 9 18.6 5.0 4.2 2.5 N
48 MURUGESAN 55 M 137811
MLN.LOW/LO
A 10 P/AC NIL WD N RH I WI, RI 12 16.8 4.8 3.5 1.5 N
49 LOGAIYAN 50 M 123521
LS, CONST,
LOW/LOA 3 C/DC NIL MD N LH II
PI, WI,
   RI 14 7.2 4.1 2.8 2.1 N
50 MUNIYAMMA 46 F 107368
A, M, LS,
LOW/LOA 5 UP/AC LN+ PD N RH III NIL 9 2.6 2.2 2.1 1.7 N
